Ignite Creation Date:
2025-12-24 @ 5:25 PM
Ignite Modification Date:
2026-02-24 @ 11:01 AM
Study NCT ID:
NCT05403450
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-06-03
First Post:
2022-05-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Sponsor:
Taiho Oncology, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-06-23
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-23
First Submit QC Date:
None
Study First Post Date:
2022-06-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-30
Last Update Post Date:
2025-06-03
Last Update Post Date Type:
ACTUAL